Category: Gynecological

INVO Bioscience touts South American infertility treatment trial results

February 5, 2010 by MassDevice staff

INVO Bioscience (OTC:IVOB) is touting the results of a South American clinical trial it says showed its INVOcell, a small capsule used to incubate eggs and sperm as an alternative to conventional infertility treatments, posted a 36 percent success rate in impregnating infertile women.

The Beverly, Mass.-based company said more than two-thirds of the 50 patients enrolled at the Center of Fertility and Sterility in Bogota, Colombia, reached the study's endpoint of clinical pregnancy, defined as a fetal heartbeat at seven weeks. That success rate puts the technique on par with other infertility treatments, company officials said, but with a much lower multiple pregnancy rate of 6 percent.

Hologic's Q1 bottom line drops 31 percent

February 1, 2010 by MassDevice staff

Hologic Inc. (NSDQ:HOLX) took another tangible hit to its bottom line, writing off about $100 million worth of intangibles during the first quarter.

In all, the Bedford, Mass.-based women's health company peeled off a little more than $100 million worth of intangible assets, an accounting term for the value of the perceived advantage a company has over its competitors. The hit, combined with another $18 million charge to adopt new changes to its accounting code, pushed Hologic's bottom line down 31 percent during the three months ended Dec. 26, 2009.

Federal judge deals blow to Conceptus infringement suit against Hologic

November 12, 2009 by MassDevice staff

A federal judge in California dealt a blow to a Conceptus Inc. (CPTS) lawsuit against Hologic Inc. (HOLX), alleging infringement of five patents for its Essure female sterilization system.

Essure, the Mountain View, Calif.-based company's sole product, uses a flexible coil partly made of copper to permanently block the fallopian tubes. The device is delivered via a trans-cervical catheter.

BioSphere Medical narrows net loss

July 30, 2009 by MassDevice staff

Customer outreach and other marketing efforts may be starting to pay off for Biosphere Medical Inc.

The Rockland, Mass.-based maker of microscopic polymer beads reported $8.1 million in sales during the three months ended June 30, with a 13 percent jump in U.S. sales of the company's interventional gynecology products pacing much of that gain.

The net loss for the period was $677,000, which compares with a $1.3 million loss on $7.6 million in sales during the June 2008 quarter.

Hologic marks 1 million NovaSure procedures

July 28, 2009 by MassDevice staff

Hologic Inc. said 1 million women have undergone its NovaSure global endometrial ablation treatment.

The system is used to treat menorrhagia, or heavy menstrual bleeding, using a 90-second burst of low-frequency radio energy in a roughly 5-minute outpatient procedure.

The Bedford, Mass.-based women's health products maker said U.S. physicians performed about 312,000 GEA procedures last year, about 205,000 using the NovaSure device, making Hologic's market share roughly 66 percent.

FDA approves Hologic sterilization treatment

July 7, 2009 by MassDevice staff

The Food & Drug Administration gave the nod to Hologic Inc.'s Adiana sterilization treatment, which uses a minimally invasive natural orifice surgical technique to provide permanent contraception.

The Bedford women's health products maker said the the federal safety monitor gave pre-market approval for procedure, which involves threading an endoscope through the vagina, cervix and uterus into the fallopian tubes, where radiofrequency energy is applied to small sections of the tube.